Allecra Therapeutics and Acino Sign Exclusive Licensing and Supply Agreement for Allecra’s Novel Antibiotic EXBLIFEP® in Gulf Cooperation Council countries and South Africa
24 juin 2024 03h00 HE
|
Acino International AG
Saint-Louis, France and Weil am Rhein, Germany and Zurich, Switzerland, June 24, 2024 (GLOBE NEWSWIRE) -- Allecra Therapeutics (“Allecra”) and Acino today announced the signing of an exclusive...
Peri-Implantitis Treatment Market revenue to surpass USD 5 Billion by 2035, says Research Nester
28 sept. 2023 05h00 HE
|
Research Nester
New York, Sept. 28, 2023 (GLOBE NEWSWIRE) -- The global peri-implantitis treatment market size is projected to expand at ~8% CAGR between 2023 and 2035. The market is expected to garner a revenue of...
Nonvenereal Syphilis Treatment Market revenue to hit USD 440 Million by 2035, says Research Nester
26 sept. 2023 07h30 HE
|
Research Nester
New York, Sept. 26, 2023 (GLOBE NEWSWIRE) -- The global nonvenereal syphilis treatment market size is predicted to grow at a CAGR of over ~9% from 2023 to 2035. The market is projected to garner a...
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
10 août 2023 16h15 HE
|
OpGen, Inc.
Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D...
Andira Pharmaceuticals’ US Patent Allowed in Breakthrough Therapeutic Treatment to Address Deadly Antibiotic-Resistant Infections
10 août 2023 08h00 HE
|
US Capital Global
San Francisco, California, USA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- US Capital Global Securities LLC, an affiliate of US Capital Global, recently launched an investment opportunity of up to $5 million...
OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND
19 juil. 2023 07h30 HE
|
OpGen, Inc.
All milestones successfully met, including antibiotic stewardship module, mobile and cloud-based data access as well as comprehensive next generation sequencing resultsTriggers additional milestone...
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe
26 juin 2023 07h30 HE
|
OpGen, Inc.
Patent EP 3 332 028 B1 granted by the European Patent Office covers the identification and use of genomic variants for the diagnosis of antibiotic resistant bacteria.The opposition division of...
Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances demonstrating potent in vitro and in vivo antimicrobial activity against MDR and XDR Enterobacteriaceae, including carbapenem-resistant and colistin-resistant strains
07 juin 2023 01h15 HE
|
Spexis AG
ALLSCHWIL, Switzerland, June 06, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced the publication of...
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
15 mai 2023 16h15 HE
|
OpGen, Inc.
Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of approximately 94% compared to the first quarter of 2022Expanded U.S. growth opportunities with the Unyvero...
OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern Time
08 mai 2023 07h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., May 08, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter...